Pharmaceuticals

Jaguar Health

Jaguar Health released FY2025 9 Months Earnings on November 14 Pre-Market EST, actual revenue USD 8.276 M, actual EPS USD -33.2333

Jaguar Health released FY2025 Q3 earnings on November 14 Pre-Market (EST), actual revenue USD 3.083 M (forecast USD 3.73 M), actual EPS USD -6.2794 (forecast USD -5.08)

Jaguar Health to release FY2025 Q3 earnings report on November 17, pre-market EST, with forecasted revenue of USD 3.73 M and EPS of USD -5.08

Jaguar Health Inc. Makes Progress in Developing Drug for Rare Childhood Disease

Jaguar Health released FY2025 Semi-Annual Earnings on August 14 Pre-Market EST, actual revenue USD 5.193 M, actual EPS USD -26.7786

Jaguar Health released FY2025 Q2 earnings on August 14 Pre-Market EST, actual revenue USD 2.979 M (forecast USD 3.27 M), actual EPS USD -10.2553 (forecast USD -7.13)

Jaguar Health to release FY2025 Q2 earnings pre-market on August 14, 2025 (EST), forecast revenue USD 3.27 M, EPS USD -7.13

Jaguar Health Inc. Pushes for European Approval of Canalevia-CA1

Jaguar Health amends royalty agreement

Jaguar Health Announces Positive Clinical Trial Results for Crofelemer

Jaguar Health Seeks EMA Approval for Canalevia

Jaguar Health Rare Disease Drug Clinical Trials Progress

Jaguar Health CEO to Provide Company Update at Emerging Growth Conference

Jaguar Health Inc. Establishes Canalevia-CA1 Study Site

Jaguar Health to Hold Virtual Conference Call on OnTarget Phase 3 Trial Results

Jaguar Health's crofelemer drug progress recognized by FDA

Jaguar Health Inc. Participates in Lytham Partners Spring Virtual Fireside Chat

Jaguar Health Inc. Completes $1.5 Million Registered Direct Offering

Jaguar Health Initiates Phase II Clinical Trial for Crofelemer

Jaguar Health Reports Increased Quarterly Operating Loss

Luminar Tech

Novabay Pharmac

Mint Incorporation

Autozi Internet Tech Global

GD Culture

Impact BioMedical

Tradr 2X Long FLY Daily ETF

Leverage Shares 2X Long CRWV Daily ETF

T-REX 2X Long CRWV Daily Target ETF

Eli Lilly

ROCHE HOLDINGS AG

Roche

Astrazeneca

NOVARTIS AG

Novo Nordisk AS

Chugai Pharmaceutical

UCB S.A.

Daiichi Sankyo

Otsuka Pharmaceutical

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap